Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

Armata posts $54.9M Q3 profit on one-time gain, with Phase 3 trial still pending FDA sign-off.

What the company is saying

Armata Pharmaceuticals, led by CEO Dr. Deborah Birx, frames its Q3 update around operational progress toward launching the pivotal Phase 3 superiority trial of AP-SA02 for complicated Staphylococcus aureus bacteremia. The company highlights completion of four engineering runs and one cGMP production run for AP-SA02 at its Los Angeles facility, and ongoing FDA protocol negotiations. Armata emphasizes regulatory momentum, citing FDA Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product designations for AP-SA02, and an agreed pediatric study plan with studies deferred until after adult Phase 3 data. The company stresses continued U.S. Department of War backing, with $3.7 million in new non-dilutive funding this quarter, bringing total DoW support to $32.4 million. Two new U.S. patents extending protection for AP-SA02 and AP-PA02 are also highlighted. The tone is confident, attributing the swing to $54.9 million net income to a $69.6 million gain from convertible loan revaluation, while acknowledging increased R&D and administrative costs.

What the data suggests

The financials show a sharp turnaround: Q3 2026 net income was $54.9 million, up from a $26.7 million loss in Q3 2025, driven by a $69.6 million gain from changes in the fair value of a convertible loan. Grant and award revenue rose to $3.2 million from $1.2 million, while R&D expenses increased to $6.8 million and G&A to $3.7 million. Operating loss narrowed slightly to $7.4 million. Cash and equivalents doubled to $18.3 million since year-end 2025, supported by $3.7 million in new DoW funding (cumulative $32.4 million). Total assets rose to $84.5 million, but current liabilities surged to $186.8 million, reflecting reclassification of debt and convertible loans. Stockholders' deficit improved to ($174.1 million) from ($218.6 million). The profit is non-recurring, as it stems from a one-time convertible loan revaluation, not from operations. Operationally, the Phase 3 trial has not yet started and remains dependent on FDA protocol concurrence. Patents now protect AP-SA02 until at least 2041 and AP-PA02 until 2043.

Analysis

The announcement is generally positive in tone, highlighting regulatory achievements, new funding, patent issuances, and preparations for a pivotal Phase 3 trial. Several key claims are realised and well-supported, such as the completion of engineering and cGMP runs, receipt of FDA designations, new patents, and a significant improvement in net income (driven by a gain from convertible loan revaluation). However, a substantial portion of the narrative focuses on forward-looking milestones, such as the anticipated initiation of the Phase 3 study in the second half of 2026, which is still pending FDA protocol concurrence. While the company claims operational readiness and infrastructure establishment, these are not substantiated with quantitative or third-party evidence. The improvement in net income is largely non-operational, stemming from a fair value gain rather than core business growth. The overall hype is moderate, as the language is optimistic but not excessively promotional, and most forward-looking claims are plausible given the disclosed progress.

Risk flags

• ●The Q3 profit is entirely due to a $69.6 million gain from convertible loan revaluation, not from recurring operations. This introduces volatility and means future profitability is not assured unless core business performance improves.
• ●The Phase 3 trial for AP-SA02 has not begun and is contingent on FDA protocol concurrence. Delays or failure to secure protocol approval could push back key milestones and impact future funding or partnership opportunities.
• ●Current liabilities have ballooned to $186.8 million, largely due to reclassification of convertible loans and term debt, raising liquidity and balance sheet risk if additional funding or refinancing is not secured.
• ●Despite increased government funding, Armata remains dependent on non-dilutive awards and external capital to fund ongoing R&D and operations, with cash of $18.3 million likely insufficient for long-term needs if trial timelines slip.
• ●The company’s narrative emphasizes regulatory designations and operational readiness, but lacks hard evidence of trial initiation or enrollment, making execution risk significant for the next phase.

Bottom line

Armata’s Q3 financials are flattered by a one-off $69.6 million gain from convertible loan revaluation, producing a $54.9 million net profit and $1.15 basic EPS, but core operations remain loss-making with a $7.4 million operating loss. Cash has improved to $18.3 million, helped by $3.7 million in new DoW funding, but current liabilities have surged to $186.8 million, highlighting ongoing balance sheet pressure. The Phase 3 AP-SA02 trial is not yet underway and still requires FDA protocol approval, so near-term catalysts are uncertain and execution risk is high. Regulatory wins and new patents strengthen the long-term case, but investors should recognize that the current profit is not sustainable without operational progress. The most important takeaway is that Armata’s future hinges on actually launching and enrolling its pivotal Phase 3 trial—until then, financial results are driven by accounting items and government support, not commercial traction.

Announcement summary

(NYSE American: ARMP) Armata Pharmaceuticals, Inc. announced financial results for its third quarter ended September 30, 2026, and provided a corporate update. Dr. Deborah Birx, Chief Executive Officer, stated that the company is advancing toward initiating the Phase 3 superiority study of AP-SA02, with operational infrastructure established and manufacturing capabilities in place. Armata continued discussions with the FDA to finalize the Phase 3 study design for AP-SA02, submitted protocol revisions, and responded to all Clinical, Chemistry, Manufacturing, and Controls (CMC), and Regulatory comments from the FDA's End-of-Phase 2 meeting. Four engineering runs of AP-SA02 were completed at the company's in-house cGMP manufacturing facility in Los Angeles, California, and one cGMP production run and vialing of AP-SA02 drug product was completed in Q3 2026. The company executed contracts with clinical research organizations and continued negotiating clinical trial agreements with initial U.S. clinical trial sites. The Phase 3 study is expected to initiate in the second half of 2026, pending FDA protocol concurrence. AP-SA02 received FDA Breakthrough Therapy designation for adjunct treatment of complicated bacteremia caused by MSSA or MRSA, and now holds Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product designations. The FDA agreed to an Initial Pediatric Study Plan (Agreed iPSP) for future pediatric evaluation of AP-SA02, with pediatric studies deferred pending adult Phase 3 data. Armata received $3.7 million in additional non-dilutive funding from the U.S. Department of War (DoW) for AP-SA02 Phase 3 execution, bringing cumulative DoW funding under the award to approximately $32.4 million, including $28.7 million previously provided. New AP-SA02 data was presented at the 20th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI) in Banff, Alberta, Canada, and a peer-reviewed article was published in the Journal of Molecular Biology. Two U.S. patents were issued: U.S. Patent No. 12,751,983 (issued October 6, 2026) for methods of treating S. aureus infections with AP-SA02 (protection until at least February 2041), and U.S. Patent No. 12,594,312 (issued April 7, 2026) for methods of treating Pseudomonas infections with AP-PA02 (protection expected until January 2043). For the three months ended September 30, 2026, grant and award revenue was $3.2 million, compared to $1.2 million in 2025. Research and development expenses were approximately $6.8 million, compared to $5.8 million in 2025. General and administrative expenses were approximately $3.7 million, compared to $3.1 million in 2025. Loss from operations was approximately $7.4 million, compared to $7.8 million in 2025. Other income, net, was approximately $62.2 million, compared to other expense, net, of $18.9 million in 2025, including a gain of $69.6 million from changes in the fair value of the convertible loan (compared to a loss of $14.6 million in 2025). Net income for Q3 2026 was $54.9 million, or $1.15 earnings per share basic and ($0.24) loss per share diluted, compared to a net loss of ($26.7) million, or $(0.74) loss per share basic and diluted in 2025. As of September 30, 2026, Armata held approximately $18.3 million in unrestricted cash and cash equivalents, compared to $8.7 million as of December 31, 2025. As of November 6, 2026, 37,192,632 common shares were outstanding. Condensed consolidated balance sheets show total assets of $84,478,000 as of September 30, 2026, and $76,882,000 as of December 31, 2025. Total current liabilities were $186,778,000 as of September 30, 2026, and $8,947,000 as of December 31, 2025. Total liabilities were $258,606,000 as of September 30, 2026, and $295,478,000 as of December 31, 2025. Total stockholders' deficit was ($174,128,000) as of September 30, 2026, and ($218,596,000) as of December 31, 2025. For the three months ended September 30, 2026, grant and award revenue was $3,171,000, research and development expenses were $6,830,000, general and administrative expenses were $3,724,000, operating loss was $7,383,000, interest income was $206,000, interest expense was $7,561,000, change in fair value of the Convertible Loan was $69,595,000, total other income (expense), net, was $62,240,000, net income was $54,857,000, income attributable to participating warrants was $12,219,000, net income attributable to common stockholders was $42,638,000, net income per share basic was $1.15, and net loss per share diluted was ($0.24). Weighted average shares outstanding basic were 37,181,573 and diluted were 62,679,380 for the three months ended September 30, 2026.

Disagree with this article?